Abstract:Ischemia is a multifactorial pathology characterized by different events evolving in the time. After ischemia a primary damage due to the early massive increase of extracellular glutamate is followed by activation of resident immune cells, i.e microglia, and production or activation of inflammation mediators. Protracted neuroinflammation is now recognized as the predominant mechanism of secondary brain injury progression. Extracellular concentrations of ATP and adenosine in the brain increase dramatically during ischemia in concentrations able to stimulate their respective specific P2 and P1 receptors. Both ATP P2 and adenosine P1 receptor subtypes exert important roles in ischemia. Although adenosine exerts a clear neuroprotective effect through A1 receptors during ischemia, the use of selective A1 agonists is hampered by undesirable peripheral effects. Evidence up to now in literature indicate that A2A receptor antagonists provide protection centrally by reducing excitotoxicity, while agonists at A2A (and possibly also A2B) and A3 receptors provide protection by controlling massive infiltration and neuroinflammation in the hours and days after brain ischemia. Among P2X receptors most evidence indicate that P2X7 receptor contribute to the damage induced by the ischemic insult due to intracellular Ca(2+) loading in central cells and facilitation of glutamate release. Antagonism of P2X7 receptors might represent a new treatment to attenuate brain damage and to promote proliferation and maturation of brain immature resident cells that can promote tissue repair following cerebral ischemia. Among P2Y receptors, antagonists of P2Y12 receptors are of value because of their antiplatelet activity and possibly because of additional anti-inflammatory effects. Moreover strategies that modify adenosine or ATP concentrations at injury sites might be of value to limit damage after ischemia. This article is part of the Special Issue entitled 'Purines in Neurodegeneration and Neuroregeneration'.

Purinergic signaling and the functioning of the nervous system cells

P2X and P2Y Receptors—Role in the Pathophysiology of the Nervous System

The Role of Purinergic Receptors in Neural Repair and Regeneration after Spinal Cord Injury

Purinergic modulation of microglial cell activation

Purine and purinergic receptors in health and disease

Editorial - Purinergic signalling: 50 years

Introduction to Purinergic Signaling

Comprehensive Insights into Potential Roles of Purinergic P2 Receptors on Diseases: Signaling Pathways Involved and Potential Therapeutics

Purinergic Signaling and its Role in the Stem Cell Differentiation

Modulation of excitatory neurotransmission by neuronal/glial signalling molecules: interplay between purinergic and glutamatergic systems

The Role of Purinergic Signaling in Microglial Responses

Purinergic Signaling： a Novel Mechanism in Immune Surveillance

From purines to purinergic signalling: molecular functions and human diseases

Purinergic signalling during development and ageing

Regulation of Microglial Functions by Purinergic Mechanisms in the Healthy and Diseased CNS

Long-term (trophic) purinergic signalling: purinoceptors control cell proliferation, differentiation and death

Purinergic Regulation of Neutrophil Function

P2Y6 receptor and immunoinflammation

The Therapeutic Potential of Purinergic Receptors in Alzheimer’s Disease and Promising Therapeutic Modulators

Regulation of GABAergic neurotransmission by purinergic receptors in brain physiology and disease

Purinergic signalling in brain ischemia